CN1488399A - 尖吻蝮蛇凝血酶用作治疗出血性疾病的药物 - Google Patents
尖吻蝮蛇凝血酶用作治疗出血性疾病的药物 Download PDFInfo
- Publication number
- CN1488399A CN1488399A CNA031401546A CN03140154A CN1488399A CN 1488399 A CN1488399 A CN 1488399A CN A031401546 A CNA031401546 A CN A031401546A CN 03140154 A CN03140154 A CN 03140154A CN 1488399 A CN1488399 A CN 1488399A
- Authority
- CN
- China
- Prior art keywords
- halase
- hemorrhage
- treatment
- medicine
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001505404 Deinagkistrodon acutus Species 0.000 title claims abstract description 12
- 108090000190 Thrombin Proteins 0.000 title description 13
- 208000031169 hemorrhagic disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 36
- 229940079593 drug Drugs 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000002347 injection Methods 0.000 claims abstract description 11
- 239000007924 injection Substances 0.000 claims abstract description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 5
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 4
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 4
- 208000032843 Hemorrhage Diseases 0.000 claims description 58
- 108010027612 Batroxobin Proteins 0.000 claims description 39
- 230000000694 effects Effects 0.000 claims description 15
- 229960002210 batroxobin Drugs 0.000 claims description 10
- 239000003998 snake venom Substances 0.000 claims description 9
- 238000005259 measurement Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000006196 drop Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000865 liniment Substances 0.000 claims 1
- 229940040145 liniment Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 230000000025 haemostatic effect Effects 0.000 abstract description 12
- 229940030225 antihemorrhagics Drugs 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 101000772006 Bombus ignitus Venom serine protease Bi-VSP Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 230000002008 hemorrhagic effect Effects 0.000 abstract 1
- 150000002402 hexoses Chemical class 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 230000000740 bleeding effect Effects 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 17
- 210000001772 blood platelet Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 239000008227 sterile water for injection Substances 0.000 description 12
- 229960004072 thrombin Drugs 0.000 description 12
- 240000007711 Peperomia pellucida Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 230000023555 blood coagulation Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 108010073385 Fibrin Proteins 0.000 description 7
- 102000009123 Fibrin Human genes 0.000 description 7
- 108010049003 Fibrinogen Proteins 0.000 description 7
- 102000008946 Fibrinogen Human genes 0.000 description 7
- 229950003499 fibrin Drugs 0.000 description 7
- 229940012952 fibrinogen Drugs 0.000 description 7
- 206010065441 Venous haemorrhage Diseases 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 241000271042 Gloydius halys Species 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000003527 fibrinolytic agent Substances 0.000 description 4
- 230000003480 fibrinolytic effect Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 108010088842 Fibrinolysin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000005686 Serum Globulins Human genes 0.000 description 3
- 108010045362 Serum Globulins Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000002110 toxicologic effect Effects 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 230000002227 vasoactive effect Effects 0.000 description 3
- 241000271511 Bothrops atrox Species 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000271897 Viperidae Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000014759 blood platelet disease Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 108010073651 fibrinmonomer Proteins 0.000 description 2
- 229940001501 fibrinolysin Drugs 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241001062472 Stokellia anisodon Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000504 antifibrinolytic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001723 fibrinogenic effect Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000009939 hypertensive encephalopathy Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 239000003439 teratogenic agent Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (5)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031401546A CN1218747C (zh) | 2003-08-14 | 2003-08-14 | 尖吻蝮蛇凝血酶用作治疗出血性疾病的药物 |
AU2003292882A AU2003292882A1 (en) | 2003-08-14 | 2003-12-08 | Thrombin from venom of agkistrodon acutus used as drugs for the treatment of haemorrhage |
PCT/CN2003/001048 WO2005017139A1 (fr) | 2003-08-14 | 2003-12-08 | Thrombine provenant de venin de agkistrodon acutus utilisee comme medicament pour traiter une hemorragie |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031401546A CN1218747C (zh) | 2003-08-14 | 2003-08-14 | 尖吻蝮蛇凝血酶用作治疗出血性疾病的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1488399A true CN1488399A (zh) | 2004-04-14 |
CN1218747C CN1218747C (zh) | 2005-09-14 |
Family
ID=34155227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031401546A Expired - Lifetime CN1218747C (zh) | 2003-08-14 | 2003-08-14 | 尖吻蝮蛇凝血酶用作治疗出血性疾病的药物 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN1218747C (zh) |
AU (1) | AU2003292882A1 (zh) |
WO (1) | WO2005017139A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102757948A (zh) * | 2012-05-28 | 2012-10-31 | 广东瑞昇药业有限公司 | 尖吻蝮蛇凝血酶及其分离方法 |
WO2014101743A1 (zh) * | 2012-12-26 | 2014-07-03 | Li Hewei | 一种冻干赋型制剂及其制备方法 |
CN105535949A (zh) * | 2015-12-28 | 2016-05-04 | 重庆骑士医院 | 巴曲酶酵母发酵中药的方法 |
WO2019010602A1 (zh) * | 2017-07-10 | 2019-01-17 | 中山大学 | 一种尖吻蝮蛇凝血酶重组蛋白的表达方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100494366C (zh) | 2006-10-19 | 2009-06-03 | 康辰医药股份有限公司 | 血凝酶 |
CN101358184A (zh) * | 2008-09-27 | 2009-02-04 | 康辰医药股份有限公司 | 尖吻蝮蛇蛇毒血凝酶 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1060806C (zh) * | 1997-11-12 | 2001-01-17 | 中国科学院上海生物化学研究所 | 尖吻蝮蛇蛇毒类凝血酶的基因序列 |
CN1151254C (zh) * | 2001-01-08 | 2004-05-26 | 中国药科大学 | 一种防治血栓性疾病的新的蛇毒类凝血酶结构及纯化 |
CN1159438C (zh) * | 2001-04-29 | 2004-07-28 | 中国科学院昆明动物研究所 | 一种尖吻蝮蛇毒凝血酶及其生产方法 |
CN1159437C (zh) * | 2001-04-29 | 2004-07-28 | 中国科学院昆明动物研究所 | 尖吻蝮蛇毒凝血酶及其生产方法 |
-
2003
- 2003-08-14 CN CNB031401546A patent/CN1218747C/zh not_active Expired - Lifetime
- 2003-12-08 AU AU2003292882A patent/AU2003292882A1/en not_active Abandoned
- 2003-12-08 WO PCT/CN2003/001048 patent/WO2005017139A1/zh active Application Filing
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102757948A (zh) * | 2012-05-28 | 2012-10-31 | 广东瑞昇药业有限公司 | 尖吻蝮蛇凝血酶及其分离方法 |
CN102757948B (zh) * | 2012-05-28 | 2014-02-05 | 广东瑞昇药业有限公司 | 尖吻蝮蛇凝血酶及其分离方法 |
WO2014101743A1 (zh) * | 2012-12-26 | 2014-07-03 | Li Hewei | 一种冻干赋型制剂及其制备方法 |
CN105535949A (zh) * | 2015-12-28 | 2016-05-04 | 重庆骑士医院 | 巴曲酶酵母发酵中药的方法 |
WO2019010602A1 (zh) * | 2017-07-10 | 2019-01-17 | 中山大学 | 一种尖吻蝮蛇凝血酶重组蛋白的表达方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2005017139A1 (fr) | 2005-02-24 |
AU2003292882A1 (en) | 2005-03-07 |
CN1218747C (zh) | 2005-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0302754B1 (en) | Stable aqueous thrombin solution | |
DE60112429T2 (de) | Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen | |
CN1121224C (zh) | 含有抗-Xa活性化合物和血小板聚集拮抗化合物的药物组合物 | |
CN107405391B (zh) | 治疗外伤患者中的出血的血小板微粒的全身和局部应用 | |
AP1185A (en) | Novel pharmaceutical composition for the use in emergency treatment and preparation method thereof. | |
JP2001515460A (ja) | 血漿タンパク質液体製剤の製造法と使用法 | |
WO1997019687A9 (en) | Methods of production and use of liquid formulations of plasma proteins | |
EP1275397B1 (de) | Arzneimittel zur lokalen Anwendung | |
CN100525777C (zh) | 一种解聚海参糖胺聚糖组合物及其制备方法和用途 | |
WO1998058661A1 (en) | Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function | |
KR101117861B1 (ko) | 포르시토사이드 주사제와 그 제조 방법 | |
Mariani et al. | Treatment of congenital factor VII deficiency with a new concentrate | |
KR101127127B1 (ko) | 고농도 피브리노겐 용액의 제조 방법 및 이를 이용한 피브린 실란트 제품의 제조방법 | |
CN1218747C (zh) | 尖吻蝮蛇凝血酶用作治疗出血性疾病的药物 | |
JPH03215430A (ja) | 関節腔抗凝固剤 | |
Brophy et al. | Warfarin resistance in a patient with short bowel syndrome | |
JPS62255430A (ja) | 哺乳動物の脈管病を治療する方法 | |
Bruning et al. | Prothrombal: a new concentrate of human prothrombin complex for clinical use | |
EP1997504A1 (en) | Novel antithrombotic agent | |
CN1287851C (zh) | 骨肽氯化钠注射液及其制备工艺 | |
US20070275086A1 (en) | Use of Increased Molecular-Weight Hirudin as an Anticoagulant in Extracorporeal Kidney Replace Therapy | |
CN101812436B (zh) | 一种尖吻蝮蛇蛇毒类凝血酶及其制备方法和应用 | |
CN1548534A (zh) | 一种蛇毒凝血酶及其生产方法与应用 | |
CN108310371B (zh) | 一种降血脂药物组合物及其用途 | |
CN100368017C (zh) | 一种具有促凝血作用的复方生物组分及其药物制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: GUANGDONG SHUNFENG PHARMACEUTICAL CO.,LTD. Assignor: Wu Zhong Contract fulfillment period: 2007.7.5 to 2022.7.4 Contract record no.: 2008440000281 Denomination of invention: Medicinal use of agkistrodon acutus thrombase for treating hemorrhagic disease Granted publication date: 20050914 License type: Exclusive license Record date: 20081024 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2007.7.5 TO 2022.7.4; CHANGE OF CONTRACT Name of requester: GUANGDONG SHUNFENG PHARMACEUTICAL CO., LTD. Effective date: 20081024 |
|
EM01 | Change of recordation of patent licensing contract | ||
EM01 | Change of recordation of patent licensing contract |
Change date: 20140124 Contract record no.: 2008440000281 The licensee after: GUANGDONG CHINA RESOURCES SHUNFENG PHARMACEUTICAL Co.,Ltd. The licensee before: GUANGDONG SHUNFENG PHARMACEUTICAL CO.,LTD. |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: GUANGDONG CHINA RESOURCES SHUNFENG PHARMACEUTICAL Co.,Ltd. Assignor: Wu Zhong Contract record no.: 2008440000281 Date of cancellation: 20140303 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU RUIKANG BIOLOGICAL PHARMACEUTICAL CO., L Free format text: FORMER OWNER: WU ZHONG Effective date: 20150703 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150703 Address after: 510530 Yonghe Yongsheng Road 10, Guangzhou economic and Technological Development Zone, Guangdong Patentee after: GUANGZHOU YOUCARE BIOPHARMACEUTIS CO.,LTD. Address before: 510275 Guangdong province Guangzhou city Xingang Road West District of Zhongshan University 745-1-303 Patentee before: Wu Zhong |
|
DD01 | Delivery of document by public notice |
Addressee: GUANGZHOU YOUCARE BIOPHARMACEUTIS CO.,LTD. Document name: Notification of Passing Examination on Formalities |
|
CX01 | Expiry of patent term |
Granted publication date: 20050914 |
|
CX01 | Expiry of patent term |